![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/nasus-pharma-announces-ground-breaking-five-years-stability-of-its-fmxin002-nasal-epinephrine-powder-for-severe-allergy-and-anaphylaxis-302215369.html
https://www.prnewswire.com/news-releases/nasus-pharma-announces-positive-clinical-results-of-recent-phase-2-study-with-fmxin002-intranasal-epinephrine-302005774.html
https://www.prnewswire.com/news-releases/nasus-pharma-announces-publication-of-its-positive-clinical-results-with-fmxin002-intranasal-powder-epinephrine-spray-in-the-journal-of-allergy-and-clinical-immunology-in-practice-301895373.html
https://www.prnewswire.com/news-releases/nasus-pharma-announces-clinical-data-demonstrating-efficacy-of-taffix--intranasal-antiviral-protection-against-common-cold-and-upper-respiratory-infection-301431485.html
https://www.prnewswire.com/news-releases/taffix-r-recupera-la-aprobacion-de-comercializacion-en-espana-876429672.html
https://www.prnewswire.com/news-releases/taffix-regains-marketing-approval-in-spain-301355680.html
https://www.prnewswire.com/news-releases/taffix-blocks-the-delta-variant-of-sars-cov-2-in-addition-to-the-alpha-uk-and-beta-south-african-variant-301336316.html
https://www.prnewswire.com/news-releases/taffix-r-blocks-the-delta-variant-of-sars-cov-2-in-addition-to-the-alpha-uk-and-beta-south-african-variant-834336177.html
https://www.prnewswire.com/news-releases/nasus-pharma-announces-positive-results-from-a-pilot-clinical-study-of-fmxin002-intranasal-powder-epinephrine-spray-in-patients-with-seasonal-allergic-rhinitis-301318141.html
https://www.prnewswire.com/il/news-releases/nasus-pharma-announces-data-demonstrating-in-vitro-efficacy-of-taffix-intranasal-antiviral-spray-against-sars-cov-2-british-and-south-african-variants-301273695.html